Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Change in Account Payables data on file, last reported at $1.9 million in Q2 2026.

• On a quarterly basis, Change in Account Payables rose 169.88% year-over-year to $1.9 million in Q2 2026; TTM through May 2026 was $6.7 million, a 138.86% increase from a year earlier, with the FY2025 full-year figure at -$630000.0, down 112.09% from the prior year.
• Change in Account Payables for Q2 2026 stood at $1.9 million, up from -$461000.0 in the prior quarter.
• Over the last five years, Change in Account Payables for NRIX reached as high as $7.6 million in Q4 2024 and fell as low as -$3.2 million in Q1 2025.
• Historically, Change in Account Payables has averaged $427166.7 across 5 years, with a median of -$282000.0 in 2022.
• Across the five-year window, Change in Account Payables soared 617.24% in 2023 and slumped 332.5% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at -$899000.0 in 2022, then surged by 617.24% to $4.6 million in 2023, then jumped by 63.12% to $7.6 million in 2024, then tumbled by 60.12% to $3.0 million in 2025, then sank by 38.12% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $1.9 million in Q2 2026, -$461000.0 in Q1 2026, and $3.0 million in Q4 2025.